Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Socioeconomic Status May Affect Discharge Timing After Lung Cancer Surgery
October 3rd 2023Patients with lung cancer undergoing anatomic lung resections often had one day home return after completing the surgery, but those with a lower socioeconomic status were less likely to leave the hospital the day after surgery.
Read More
2 Clarke Drive
Cranbury, NJ 08512